Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Pharmgenomics Pers Med
2012 Jan 01;5:113-23. doi: 10.2147/PGPM.S24258.
Show Gene links
Show Anatomy links
Personalized medicine and treatment approaches in non-small-cell lung carcinoma.
Vadakara J
,
Borghaei H
.
???displayArticle.abstract???
Chemotherapy has been the traditional backbone for the management of metastatic lung cancer. Multiple trials have shown the benefits of treatment with platinum doublets in lung cancer. This "one treatment fits all" approach was further refined by the introduction of targeted agents and discovery of subpopulations of patients who benefited from treatment with these agents. It has also become evident that certain histologic subtypes of non-small-cell lung cancer respond better to one cytotoxic chemotherapy versus others. This has led to the concept of using histology to guide therapy. With the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and the discovery of activating mutations in the EGFR gene, further personalization of treatment for subgroups of patients has become a reality. More recently, the presence of a fusion gene, echinoderm microtubule-associated protein-like 4 - anaplastic lymphoma kinase (EML4-ALK), was identified as the driver mutation in yet another subgroup of patients, and subsequent studies have led to approval of crizotinib in this group of patients. In this article, efforts in personalizing delivery of care based on the histological subtypes of lung cancer and the role of K-RAS and EGFR mutations, EML4/ALK translocation, and ERCC1 (excision repair cross-complementing 1) and EGFR expression in choosing appropriate treatments for patients with advanced lung cancer are discussed. This article also reviews the problem of resistance to EGFR tyrosine kinase inhibitors and the ongoing trials that target novel pathways and mechanisms that are implicated in resistance.
Al-Saleem,
Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms.
2005, Pubmed
Al-Saleem,
Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms.
2005,
Pubmed
Appels,
Development of farnesyl transferase inhibitors: a review.
2005,
Pubmed
Asano,
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay.
2006,
Pubmed
Baselga,
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
2002,
Pubmed
Bean,
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
2008,
Pubmed
Bean,
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
2007,
Pubmed
Brugger,
Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
2011,
Pubmed
Brunner,
Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.
2003,
Pubmed
Cappuzzo,
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
2010,
Pubmed
Dufort,
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC.
2011,
Pubmed
Engelman,
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
2007,
Pubmed
Escudier,
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
2007,
Pubmed
Ferrara,
The biology of VEGF and its receptors.
2003,
Pubmed
Ferrara,
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
2004,
Pubmed
Fukuoka,
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
2003,
Pubmed
Gatzemeier,
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
2007,
Pubmed
Giaccone,
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.
2006,
Pubmed
Giaccone,
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
2004,
Pubmed
Giantonio,
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
2007,
Pubmed
Greulich,
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
2005,
Pubmed
Han,
Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
2012,
Pubmed
Hanna,
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
2004,
Pubmed
Herbst,
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
2005,
Pubmed
Herbst,
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
2004,
Pubmed
Hicklin,
Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
2005,
Pubmed
Hidalgo,
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
2001,
Pubmed
Hirsch,
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
2003,
Pubmed
Hurwitz,
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
2004,
Pubmed
Jackman,
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
2007,
Pubmed
Kelly,
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
2001,
Pubmed
Kobayashi,
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
2005,
Pubmed
Kreisl,
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.
2009,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lee,
Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.
2011,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Lynch,
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
2010,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
Margolin,
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
2001,
Pubmed
Mascaux,
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis.
2005,
Pubmed
Massarelli,
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
2007,
Pubmed
McNeely,
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
2010,
Pubmed
Miller,
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.
2007,
Pubmed
Miller,
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
2008,
Pubmed
Mitsudomi,
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
2010,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Naoki,
The PCR-invader method (structure-specific 5' nuclease-based method), a sensitive method for detecting EGFR gene mutations in lung cancer specimens; comparison with direct sequencing.
2011,
Pubmed
Niho,
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
2006,
Pubmed
Nomoto,
Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis.
2006,
Pubmed
Oda,
A comprehensive pathway map of epidermal growth factor receptor signaling.
2005,
Pubmed
Olaussen,
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
2006,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Paik,
Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
2011,
Pubmed
Pao,
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
2005,
Pubmed
Pirker,
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop.
2010,
Pubmed
Pirker,
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
2009,
Pubmed
Pirker,
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
2012,
Pubmed
Riely,
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
2011,
Pubmed
Saltz,
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
2008,
Pubmed
Saltz,
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
2007,
Pubmed
Sandler,
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
2006,
Pubmed
Santos,
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient.
1984,
Pubmed
Schiller,
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
2002,
Pubmed
Schiller,
Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.
2001,
Pubmed
Sequist,
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.
2011,
Pubmed
Sequist,
Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
2011,
Pubmed
Sharma,
Epidermal growth factor receptor mutations in lung cancer.
2007,
Pubmed
Shepherd,
Erlotinib in previously treated non-small-cell lung cancer.
2005,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Suzuki,
Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products.
1990,
Pubmed
Thatcher,
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
NULL,
Pubmed
Tsao,
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
2007,
Pubmed
Vredenburgh,
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
2007,
Pubmed
Yi,
Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
2011,
Pubmed
Zhao,
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
2015,
Pubmed
Zhou,
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
2011,
Pubmed
